Profile: ACADIA Pharmaceuticals Inc (ACAD.O)
14 Mar 2014
ACADIA Pharmaceuticals Inc., incorporated in 1993, is a biopharmaceutical company focused on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The Company has four product candidates in clinical development led by pimavanserin. It holds worldwide commercialization rights to pimavanserin. In addition, the Company has a product candidate in Phase II development for chronic pains and a product candidate in Phase I development for glaucoma. The Company's clinical-stage product candidates include Pimavanserin, Alpha Adrenergic Agonists, Muscarinic Agonist and AM-831.
Pimavanserin is a new chemical entity that it discovered and have advanced to Phase III development as a first-in-class treatment for Parkinson’s disease psychosis. Pimavanserin provides an approach to treating this disorder by selectively blocking a key serotonin receptor. It is conducting several clinical trials in its Phase III program with pimavanserin for Parkinson’s disease psychosis, including a pivotal Phase III efficacy, tolerability and safety study, and open-label safety extension studies. In addition to the -020 Study, it is continuing to conduct an open-label safety extension trial, referred to as the -015 Study, involving patients with Parkinson’s disease psychosis who have completed its earlier Phase III studies, as well as patients who complete the -020 Study. Patients are eligible to participate in the -015 Study if, in the opinion of the treating physician, the patient may benefit from continued treatment with pimavanserin.
Alpha Adrenergic Agonists
In collaboration with Allergan, Inc., the Company has discovered and is developing small molecule product candidates for the treatment of chronic pain. Allergan, Inc. has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome.
The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the cause of blindness in the world. This program has reached Phase I development.
The Company has discovered and, in collaboration with Meiji Seika Pharma, is developing AM-831, a small molecule product candidate for the treatment of schizophrenia. AM-831 is a orally available small molecule that combines muscarinic m1 partial agonism with both dopamine D2 and serotonin 5-HT2A receptor antagonism. AM-831 provides the potential for a new class of pro-cognitive antipsychotic drugs. AM-831 has reached Phase I development.
The Company used its drug discovery platform to discover additional product candidates. These include two preclinical programs that provide the potential for disease-modifying therapies for treating Parkinson’s disease and other neurological disorders. In its ER-beta program, it has discovered compounds that exhibit anti-inflammatory and neuroprotective properties in preclinical models. These compounds also may address symptoms of chronic, inflammatory and neuropathic pain while avoiding the side effects associated with activating ER-alpha receptors.
The Company competes with Astra-Zeneca, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb, Otsuka Pharmaceutical, Pfizer and Allergan, Inc.
ACADIA Pharmaceuticals Inc
SUITE 100, 11085 TORREYANA ROAD
SAN DIEGO CA 92121